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tive of the model was to assess the change of disease progression due to higher 
percentage of treated patients with iv iron and subsequently the impact on the 
health care costs. Disease progression was modelled by using a sequential Markov 
model with monthly transitions of NYHA health states of the cohort. The model 
takes into account direct costs (NYHA, hospital, outpatient and iron therapy) from 
2014 and data from a systematic literature review (RCT, cohort studies and clinical 
guidelines). Results: The result of the BIA shows that an increased use of iv iron 
therapy (based on a iv iron treatment scenario- treated patients +20% and iv iron 
treated patients +10%) in Austria would lead to a positive budget impact. By treating 
ID with FCM saving effects are achieved through reduced cost in the CHF manage-
ment (NYHA class shift) and reduced hospitalizations. The overall saving effect was 
calculated as € 225,115 in 2014 to € 684,443 in the 3rd year. ConClusions: Iv iron 
therapy with FCM in iron deficient CHF patients can be associated with substantial 
cost savings based on reduced hospitalisations and improved CHF functional class 
(NYHA).
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objeCtives: Assessing the benefit of enoxaparine on healthcare budget for the 
prophylaxis of the venous thromboembolism disease (VTE) and the treatment of 
deep vein thrombosis (DVT) with and without pulmonary embolism (EP) in Spain 
and its Autonomous Communities (ACs). Methods: Prophylaxis patients were clas-
sified as moderate or high-risk according to the surgery type. The budget impact was 
estimated by comparing the cost in a scenario where 100% of the market is covered 
with enoxaparine from a scenario with only bemiparine. An additional analysis was 
performed considering the current treatment setting with all heparins available 
in the market versus a projected scenario where all patients receive enoxaparine. 
Cost estimation was based on real sales per product and pack over a year (March 
2014 to February 2015) obtained from IMS Health database (Dataview), and on the 
retail price plus the value-added tax in 2015, discounting the deductions according 
to Royal Decrees. Results: In the scenario comparing enoxaparine to bemiparine, 
the administration of enoxaparine for VTE prophylaxis would lead to a cost saving 
for the national health system of 10.138.123€ for high-risk patients and 744.684€ 
for moderate risk patients, depending on the AC savings range from 22.524€ to 
1.952.898€ and from 2.314€ to 162.328€ in patients with high and moderate risk, 
respectively. In the treatment of DVT at national level the average savings come to 
8.125.273€ , and at regional level these vary between 21.969€ and 1.671.395€ . Savings 
obtained when comparing a scenario with only enoxaparine versus the current 
setting with all heparins come to 3.368.555€ and 9.813.120€ for prophylaxis of VTE 
and treatment of DVT, respectively, at national level. ConClusions: Broader use of 
enoxaparine for the prophylaxis of VTE and treatment of DVT with and without PE in 
Spain and its ACs would lead to an economic benefit for the Spanish health system.
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objeCtives: Venous thromboembolism (VTE) is the third most common cause of 
death from cardiovascular disease after acute MI and stroke. Initial treatment of 
VTE using heparin or LMWH has been recommended by different international 
guidelines. The aim of this study was to analyze the economic impact that could 
represent the use of bemiparin compared with the conventional treatment in 
Spain. Methods: An interactive Excel model for 3 years was developed using 
data obtained through a published literature review, including treatment costs and 
complications costs, for the Spanish National Health System. Public prices + VAT 
of bemiparin and enoxaparin were used. We consider a conservative co-payment 
of 40% for all patients. Patients were treated with LMWH for 7 days. Percentages 
and costs of complications were obtain from the literature. Three scenarios were 
designed: In the first scenario, patients were treated with bemiparin or enoxaparin 
using the current marked share, in the second 100% of patients were treated with 
bemiparin and, in the third scenario, 100% of patients were treated with enoxa-
parin. Results: The budget impact (per year, same during the 3 years) of the use 
of only bemiparin resulted in a 13% of cost savings related to the current scenario 
and in a 17% of cost savings compared with only enoxaparin. Enoxaparin compared 
with the current scenario resulted in a 4% of incremental costs. Bemiparin repre-
sents savings of around € 700,000 per year compared with current treatment and 
around € 900,000 per year when it is used in a 100% of patients instead of enoxa-
parin. ConClusions: The budget impact analysis may be important when decid-
ing which LWMH to use for the treatment of VTE. This analysis provides evidence 
reinforcing the use of bemiparin as the LMWH of choice, because its use resulted in 
a budget impact reduction for the Spanish National Health System.
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intRoduCtion: Statin therapy has proved effective in reducing cardiovascular 
morbidity and mortality. However, the cost of a defined daily dose (DDD) differs 
from a statin to another, being generally atorvastatin and simvastatin the best 
choice under the criteria of cost effectiveness. objeCtives: To assess the conse-
quences in terms of outpatient pharmaceutical expenditure and DDD prescribed, 
that accounted due to the introduction of “prescription algorithms” into the elec-
tronic prescribing tool for physicians. Check whether the prescription of statins has 
been moved towards cost effective alternatives. Methods: Cross-sectional study 
outpatient management were obtained by micro-costing. Costs were expressed in 
2015 prices and exchange rate was $1.00USD= 3.00BRL. Results: It was estimated 
60,279 patients with VTE in the entire private health system, which by switching to 
rivaroxaban, would result in overall $38.4 million savings. From the single health plan 
perspective, an average of 540, 56 and 9 patients with VTE are expected for the three 
profiles and would result in savings of $343.0, $35.8 and $5.6 thousands, respectively 
in big, medium and small size plans. Cost savings are mainly associated with shorter 
length of stay with rivaroxaban. Robustness of the model was tested in deterministic 
univariate sensitivity analysis in which results remained cost saving. ConClusions: 
Rivaroxaban has potential to yield savings for VTE treatment under Brazilian private 
system perspective.
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objeCtives: Venous thromboembolism (VTE), including deep vein thrombosis 
(DVT) and pulmonary embolism (PE) represents the third most common cardio-
vascular pathology after acute coronary syndrome and stroke. Rivaroxaban, a novel 
oral simplified therapy approved for treatment of DVT and PE leads to reduction in 
thromboembolic and haemorrhagic events and does not need laboratory monitor-
ing. This study aims to evaluate the economic impact of the use of rivaroxaban for 
preventing DVT and PE in Italy. Methods: The present analysis estimates clinical 
outcomes and economic consequences of the substitution of rivaroxaban versus 
standard therapy [(low molecular weight heparin (LMWH) + vitamin K antagonists 
(VKA)] for the treatment of VTE. In the analysis we considered a progressive replace-
ment of LMWH/VKA with rivaroxaban (22%, 25%, and 27% in DVT and 12%, 16%, and 
20% in PE) over a three years time horizon. Clinical outcomes with the two alterna-
tive treatments available were estimated using data from the EINSTEIN studies, 
which directly compare rivaroxaban with LMWH/VKA. Direct healthcare costs have 
been estimated in the perspective of Italian National Health Service (INHS) (drugs, 
hospitalizations, visits and laboratory monitoring). Results: The replacement 
of LMWH/VKA with rivaroxaban in DVT and PE is associated with a reduction in 
events (recurrent symptomatic thromboembolism, major bleeding, vascular events 
and mortality). This reduction, together with the absence of laboratory monitor-
ing costs for patients treated with rivaroxaban leads to an expenditure saving for 
the INHS in the first three years of about € 8.4 million in DVT and € 3.2 million 
in PE. ConClusions: The simplified therapy with rivaroxaban, as confirmed by 
the clinical trials, may provide significant clinical advantages in terms of avoided 
events and related costs. Moreover, without the need for laboratory monitoring, the 
increase in pharmacological expenditure is completely compensated leading overall 
to significant cost savings to the INHS.
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objeCtives: The objective of this study was to perform a Budget Impact Analysis 
(BIA) assessing the introduction of Tripliam for the treatment of hypertension into 
the Italian market. Tripliam is the first and only available single-tablet triple com-
bination antihypertensive therapy containing perindopril, amlodipine and inda-
pamide, in line with current evidence-based recommendations for the treatment 
and management of hypertension. Methods: The BIA compared two different 
scenarios: Scenario 1 without a triple fixed combination therapy vs. Scenario 2 with 
the introduction of Tripliam. Population data were obtained from a Local Project 
Database by Cegedim. The time horizon considered was 3 years from the introduc-
tion of Tripliam. Total number of patients in each of the 3 years was the same for the 
two Scenarios, because the model allows only the switch of patients from the dual 
or triple combinations to the fixed dose treatment with Tripliam. The perspective 
of the Italian National Healthcare Service was considered. Results: The study 
showed that the introduction of Tripliam leads to a reduction in the quantity of pills 
taken by patients (7.014.644, 8.743.882 and 10.127.208 in Scenario 1 and 6.469.258, 
7.762.951 and 8.657.031 in Scenario 2, respectively in year 1, 2 and 3). With a cost of 
11,26 € /month, the introduction of Tripliam generates a very limited incremental 
costs in year 1 and 2 (respectively 2.977 € and 501 € ) and a saving in the third year 
(3.478 € ) over the total expenditure of 45.7, 51.9 and 56.7 respectively in year 1, 2 
and 3 in the two scenarios. ConClusions: The present study indicates that the 
introduction of Tripliam does not imply additional treatment costs, but improves 
the adherence to the therapy, thanks to the reduction in the number of pills taken 
by patients. Better adherence is also linked to a reduction in the number of hospi-
talizations and related costs.
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objeCtives: Iron deficiency (ID) is highly prevalent in chronic heart failure (CHF) 
patients and imposes a significant disease burden for CHF patients with enormous 
impact on their outcome. CHF with ID is a major reason for hospitalization and 
represents important costs for the national health care budget in Austria. Yet, only 
a small percentage of CHF patients with ID are diagnosed. Thus, the objective of 
this analysis is the evaluation of the cost saving potential through an increased 
use of intravenous iron therapy with ferric carboxymaltose (FCM) based on clinical 
trial evidence. Methods: A budget impact analysis (BIA) with a four-year’s time 
horizon was developed from the health insurance perspective. The main objec-
